PMC:521203 / 21263-22313 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/521203","sourcedb":"PMC","sourceid":"521203","source_url":"https://www.ncbi.nlm.nih.gov/pmc/521203","text":"Treating donor cells with TSA, by contrast, significantly improved development of cloned embryos. Previous reports indicated that treatment of mouse stem cells with TSA reduced development of cloned embryos [51]. The differences between these findings may be due to the variation in the concentrations of TSA used. Prior to nuclear transfer, we treated donor cells with a wide range of TSA concentrations and identified the lowest concentration capable of inducing histone hyperacetylation (1.25 μM). The lowest concentration tested (0.08 μM), did not cause hyperacetylation, but resulted in observable changes in cell morphology, similar to those described previously [65]. It was this lower concentration of TSA (0.08 μM) that improved development of cloned embryos in our study, while the higher concentration (1.25 μM) inhibited embryo development. The detrimental effect of a higher dose of TSA on embryo development may be explained by the fact that treatment of cells with high concentrations of TSA causes chromatin breaks and apoptosis [66].","tracks":[]}